Immunoreactivity Assay Services of Radioimmunoconjugates
Welcome to Rdcthera, where innovation meets precision in the realm of radioimmunoconjugate (RIC) development. As a leading contract research organization (CRO), we specialize in providing comprehensive services tailored to the biological characterization of radiopharmaceuticals, particularly in the domain of immunoreactivity assay services.
Immunoreactivity Assay of Radioimmunoconjugates
Conjugates of monoclonal antibodies with radioisotopes, drugs or toxins have great potential for specific radiolocalisation and inactivation of tumour cells. Since coupling procedures may adversely affect the antibody, quality control procedures must be applied to determine the important characteristics of the radioimmunoconjugate. The in vivo performance of radioimmunoconjugates is inextricably linked to their ability to bind antigen. Indeed, even if only a fraction of the radioimmunoconjugate exhibits reduced binding, the contrast between the tumour and background images and the therapeutic index will be affected. An important step in the basic characterization of a radioimmunoconjugate is to assess its ability to bind its target.
Fig. 1. Immunoreactivity and specificity of A33scFv-Fc. (Wei D, et al., 2015)
Our Immunoreactivity Assay Services
Rdcthera offers a comprehensive range of services tailored to meet the needs of researchers and organizations involved in the development and characterization of radioimmunoconjugates.
- Cell-Based Linear Extrapolation Assay Services
Our cell-based linear extrapolation assay provides a robust method for determining the immunoreactive fraction of radioimmunoconjugates. By employing a modified Lineweaver-Burk plot, we extrapolate results to estimate binding capacity accurately.
- Cell-Based Saturation Assay Services
With our cell-based antigen saturation assay, we offer a straightforward approach to assess the saturation binding of radioimmunoconjugates to their target antigens.
- Bead-Based Assay Services
Our bead-based radioligand binding assay overcomes the limitations of traditional cell-based assays. Our method is applicable to antibody as well as non-antibody based radioligands and is independent of the effect of target antigen density on the cells, the choice of radioisotope used to synthesise the radioligand and the temperature at which the assay is performed.
- Our Equipment and Platforms
We utilize state-of-the-art equipment and cutting-edge platforms to perform immunoreactivity assays. Our laboratories are equipped with sophisticated radiation detectors, specialized cell culture facilities, and advanced analytical instruments to ensure accurate and reliable results.
If you are interested in our services, please contact us now and our team of experts will be happy to answer any questions you may have and learn how Rdcthera can support your research and development needs.
Reference
- Wei D, Fan Q, Cai H, et al. (2015). CF750-A33scFv-Fc-Based Optical Imaging of Subcutaneous and Orthotopic Xenografts of GPA33-Positive Colorectal Cancer in Mice. Biomed Res Int. 2015:505183.
For research use only. Not intended for any clinical use.
Related Service
